|
Balance Sheet Cash Flow Statement 2600 Kelly Rd., Ste. 100 Warrington, PA 18976-3622 PA Tel. 215-488-9300 Fax 215-488-9301 |
Type: Public
On the web:
http://www.discoverylabs.com
Employees:
118
Employee growth: (3.3%)
If you're waiting to exhale, Discovery Laboratories may be able to help. The biotechnology company focuses on treatments for respiratory disorders, particularly for babies in intensive care. Its lead candidate, Surfaxin, is under FDA review for the prevention of respiratory distress syndrome in premature infants. Discovery Labs bases its therapies on surfactants, which are naturally produced by the lungs and essential for breathing. Its Aerosurf product is a surfactant therapy in aerosol form, developed as an alternative to endotracheal intubation and conventional mechanical ventilation. Other potential disease targets include acute lung injury, asthma, chronic obstructive pulmonary disease, and cystic fibrosis.
Key numbers for fiscal year ending December, 2008:
Sales: $4.6M
Net income: ($39.1)M
Officers:
Chairman and Interim CEO: W. Thomas Amick
EVP, CFO, Principal Accounting Officer, and Treasurer: John G. Cooper
SVP Commercialization and Corporate Development: Thomas F. (Tom) Miller
Competitors:
Abbott Labs
Dey
Forest Labs
